BBOT COO Idan reports initial stock and options

BridgeBio Oncology Therapeutics, Inc. executive Elmelech Idan, the COO and Principal Financial Officer, filed an initial ownership report.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. executive Elmelech Idan, the COO and Principal Financial Officer, filed an initial ownership report. He holds 14,838 shares of Common Stock, which includes 14,232 unvested restricted stock units that vest in equal quarterly installments through January 1, 2030, subject to his continuous service.

Idan also directly holds several stock option awards to buy Common Stock, including 68,310 underlying shares at an exercise price of $10.19 per share expiring March 9, 2036, and 104,539 underlying shares at $9.59 per share expiring August 25, 2035. Additional options cover 7,767 shares at $7.88 per share and 129,678 shares at $4.17 per share, with expirations in 2035 and 2034. These options generally vest in 1/48th monthly installments from various start dates, contingent on continued service.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Elmelech Idan

Role COO & Principal Financial Ofcr

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 310,294 contracts (Direct); Common Stock — 14,838 shares (Direct)

Footnotes (5)

F1. Includes 14,232 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in equal quarterly installments, subject to the Reporting Person's continuous service to the Issuer on each such date, with the final installment scheduled to vest on January 1, 2030. The RSUs will be settled in shares of Common Stock upon vesting.
F2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date
F3. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 11, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Common Stock held: 14,838 shares Unvested RSUs: 14,232 units Option at $10.19: 68,310 underlying shares +3 more

6 metrics

Common Stock held 14,838 shares Direct Common Stock holdings reported on Form 3

Unvested RSUs 14,232 units RSUs vest quarterly with final vesting on January 1, 2030

Option at $10.19 68,310 underlying shares Stock Option (Right to Buy), expiration March 9, 2036

Option at $9.59 104,539 underlying shares Stock Option (Right to Buy), expiration August 25, 2035

Option at $7.88 7,767 underlying shares Stock Option (Right to Buy), expiration April 2, 2035

Option at $4.17 129,678 underlying shares Stock Option (Right to Buy), expiration July 22, 2034

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy, continuous service, vest and become exercisable

4 terms

restricted stock units ("RSUs") financial

"Includes 14,232 unvested restricted stock units ("RSUs"), each representing a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy financial

"security_title": "Stock Option (Right to Buy)"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer on each such date"

vest and become exercisable financial

"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Elmelech Idan report owning in BridgeBio Oncology Therapeutics (BBOT) Common Stock?

Elmelech Idan reports beneficial ownership of 14,838 BridgeBio Oncology Therapeutics Common shares. This total includes 14,232 unvested restricted stock units that each convert into one share as they vest, contingent on his continued service through scheduled quarterly dates.

How many unvested RSUs does BBOT executive Elmelech Idan hold and how do they vest?

He holds 14,232 unvested restricted stock units in BridgeBio Oncology Therapeutics. These RSUs vest in equal quarterly installments, subject to his continuous service, with the final installment scheduled to vest on January 1, 2030, and are settled in Common Stock upon vesting.

What stock options does Elmelech Idan have in BridgeBio Oncology Therapeutics (BBOT)?

Elmelech Idan holds multiple stock options to buy BBOT Common Stock, including 68,310 underlying shares at $10.19, 104,539 at $9.59, 7,767 at $7.88, and 129,678 at $4.17. Each grant has its own expiration date between 2034 and 2036.

When do Elmelech Idan’s BridgeBio Oncology Therapeutics stock options vest?

His options generally vest in 1/48th monthly installments, each month after specific start dates. These start dates include May 1, 2024, April 4, 2025, August 11, 2025, and January 1, 2026, and vesting requires his continuous service with the company on each vesting date.

What is the expiration timing of Elmelech Idan’s BBOT stock options?

His BridgeBio Oncology Therapeutics stock options expire on several future dates. Expiration dates include July 22, 2034, April 2, 2035, August 25, 2035, and March 9, 2036, if the options are not exercised earlier in accordance with their terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/30/2026 - 04:16 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Elmelech Idan

(Last)

(First)

(Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2026

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	COO & Principal Financial Ofcr

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,838⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	07/22/2034	Common Stock	129,678	$4.17	D
Stock Option (Right to Buy)	⁽³⁾	04/02/2035	Common Stock	7,767	$7.88	D
Stock Option (Right to Buy)	⁽⁴⁾	08/25/2035	Common Stock	104,539	$9.59	D
Stock Option (Right to Buy)	⁽⁵⁾	03/09/2036	Common Stock	68,310	$10.19	D

Explanation of Responses:

1. Includes 14,232 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in equal quarterly installments, subject to the Reporting Person's continuous service to the Issuer on each such date, with the final installment scheduled to vest on January 1, 2030. The RSUs will be settled in shares of Common Stock upon vesting.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date

3. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 11, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR